Clinical Trials Logo

Clinical Trial Summary

The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo on exercise-induced bronchoconstriction in adult patients with asthma. Subjects will receive each study treatment on separate visits and undergo a treadmill exercise challenge test so that the effect of study treatment on exercise-induced bronchoconstriction can be evaluated


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06245551
Study type Interventional
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Status Recruiting
Phase Phase 3
Start date December 22, 2023
Completion date July 23, 2024

See also
  Status Clinical Trial Phase
Completed NCT04302610 - Do Heat and Moisture Exchange Mask Reduce EIB and Cough Severity in Asthma N/A
Completed NCT00777348 - To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol Phase 2
Completed NCT00664937 - Exercise Induced Bronchoconstriction (0476-359) Phase 1
Completed NCT00090142 - Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275) Phase 3
Completed NCT03840044 - The Effect of Physical Exercise in a Cold Air Environment on Normal Volunteers and Asthmatic Patients N/A
Completed NCT00092131 - Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270) Phase 3
Recruiting NCT05105529 - Adaptation to Ozone in Individuals With Asthma/Exercise-induced Bronchoconstriction N/A
Not yet recruiting NCT03327701 - The Effect of Benralizumab on Exercise-induced Bronchoconstriction Phase 3
Completed NCT00245570 - Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316) Phase 3
Recruiting NCT00916773 - Pulmonary Disorders During Exercise in Patients With Obstructive Sleep Apnea N/A